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Diabetic retinopathy (DR), a microangiopathy resulting 
from chronic hyperglycemia [1], affects almost 100% of 
type 1 diabetes mellitus (T1DM) patients and around 77% of 
T2DM-affected individuals who have had the disease for at 
least 20 years [2]. The earlier stage of the disease is termed 
non-proliferative diabetic retinopathy (NPDR) and is char-
acterized by increased vascular permeability and vascular 
closure. In the later stage, the disease progresses to prolifera-
tive diabetic retinopathy (PDR), a severe condition character-
ized by proliferation of new blood vessels in the retina and 
severe visual loss leading to diabetes-induced blindness [3]. 
The retina is one of the prime insulin targets where insulin 
mediates a prosurvival pathway in the retinal neurons. In 
addition, the normal retina also expresses a highly active 
basal insulin receptor/Akt signaling pathway that is stable in 
feeding and fasting [4]. Thus, disturbances in these physio-
logic processes due to insulin resistance have previously been 
implicated in DR pathology specifically in individuals with 
T2DM [5]. Insulin resistance has been significantly influ-
enced by genetic factors; therefore, it is biologically plausible 
to study the association of DR with polymorphisms in genes 
affecting insulin resistance. One such gene is peroxisome 
proliferator activated receptor gamma (PPARγ), encoding the 
PPARγ protein, a member of the PPAR subfamily belonging 
to the nuclear hormone receptor super-family with two other 
members PPARα and PPARβ/δ. Only the role of PPARγ in 
DR pathogenesis has been elucidated mainly because of the 
protein’s role in vascular permeability, inflammation, angio-
genesis, neovascularization, and insulin resistance, all of 
which contribute to the onset and severity of DR [5-8].
The members of the nuclear hormone receptor sub-family 
have three domains: a ligand-independent activation domain, 
a DNA-binding domain, and a ligand-activated domain [9]. 
The two functional isoforms of PPARγ, namely, γ1 and γ2, 
have similar DNA-binding and ligand-activated domains but 
differ by an additional 30 amino acids at the N-terminal of 
γ2 [10]. Unlike γ1, which is expressed in various tissues, γ2 
expression is restricted to adipose tissue [11] where expres-
sion is stimulated by insulin action [12]. A non-synonymous 
genetic polymorphism Pro12Ala (rs1801282) in the ligand-
independent domain of PPARγ2 is the most extensively 
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Methods: A total of 180 subjects with DR, 193 subjects with type 2 diabetes mellitus (T2DM) with no diabetic retinopa-
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polymorphism using polymerase chain reaction-restriction fragment length polymorphism.
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this protective effect was confined to proliferative DR (OR=0.4; 95% CI=0.2–0.8) with non-significant effects on the 
susceptibility of non-proliferative DR (OR=0.67; 95% CI=0.37–1.19).
Conclusions: We report a protective role of the 12Ala polymorphism against proliferative DR in individuals with T2DM 
in Pakistan.
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studied polymorphism because it renders the receptor more 
sensitive to insulin action [13]. Several studies have shown 
decreased insulin resistance and increased insulin sensitivity 
in 12Ala carriers [14-17]. Through an unknown mechanism, 
this polymorphism has been linked to T2DM [18] and its 
complications including diabetic nephropathy [19,20], but 
some studies have reported contradictory results [13,21]. 
Another study reported the Pro12Ala polymorphism was 
protective against diabetes in Caucasians but not in South 
Asians [22]. Therefore, the role of this polymorphism in DR 
etiology is still obscure.
To date, no genetic association studies have been 
conducted on individuals with DR in Pakistan. The aim of the 
present study was to determine the association of Pro12Ala 
in PPARγ2 with the onset and severity of DR in individuals 
with T2DM.
METHODS
Sample collection and DNA isolation: The present study was 
approved by the department ethics committee of the collabo-
rating institutes and conformed to the tenets of the Declara-
tion of Helsinki. Subjects who had T2DM for at least 10 years 
were recruited from collaborating hospitals. The participants 
underwent an ophthalmological examination, including 
visual acuity, slit lamp examination, and funduscopy for the 
absence or presence of retinopathy. Inclusion criteria, based 
on the American Diabetes Association criteria on diagnosis 
of T2DM, were age 18–75 years, fasting plasma glucose 
level ≥126 mg/dl, random plasma glucose concentration 
≥200 mg/dl, serum creatinine concentration ≤2.0 mg/dl, and 
glycosylated hemoglobin below 11% [10]. Those who showed 
clinical symptoms of retinopathy were classified as the DR 
group, and the rest were designated as DNR. The DR group 
was further classified into NPDR based on the presence of 
retinal microaneurysms, dot and blot or flame-shaped hemor-
rhages, hard exudates, cotton wool spots, and intraretinal 
microvascular abnormalities, and into PDR based on retinal 
neovascularization with or without preretinal hemorrhage, 
or fibrous proliferation (representing regressed neovascular-
ization). In addition to the individuals with T2DM, healthy 
normoglycemic non-retinopathic (NGNR/control) individuals 
were also recruited for the study. The inclusion criteria for 
the healthy controls were individuals who were negative for 
diabetes, hypertension, myocardial infarction, cancer, and 
retinopathy independent of diabetes.
After informed written consent was obtained, venous 
blood was collected from 180 individuals with DR, 193 
individuals with DNR, and 200 controls (NGNR). Genomic 
DNA was extracted by a standard phenol/chloroform method 
of DNA isolation [23]. Briefly, the protocol consisted of cell 
lysis and protein digestion followed by phenol-chloroform 
extraction of the peptides, and precipitation of DNA with 
ethanol. The precipitated DNA was resuspended in Tris-
EDTA buffer and stored at 4 °C before use.
Pro12Ala genotyping: Genotyping was done with the poly-
merase chain reaction-restriction fragment length polymor-
phism (PCR-RFLP) method using Yen et al.’s primers [24]. 
Briefly, the 267 bp amplified fragment was subjected to 
restriction digestion by BstUI, which resulted in digestion of 
the PCR product into two fragments of 224 and 43 bp length 
when the polymorphic site had the G allele (Ala), while the 
PCR amplicon remained uncut in the presence of the C allele 
(Pro).
Genotyping was further validated by replicating 10% of 
the samples at random with BstUI digestion and another 10% 
of the samples with HpaII digestion. The latter also has a 
restriction site at this sequence, but the cleavage pattern is 
opposite to that of BstUI, i.e., it cuts the DNA fragment in 
the presence of the C allele while the G allele remains uncut. 
The results of the replicated samples were 100% concordant 
to the original results.
Statistical analysis: The Student t test was applied using 
EpiCalc software to compare the average age of the three 
study groups. Deviation from Hardy–Weinberg equilibrium 
of genotype frequencies in the control individuals was tested 
with the goodness-of-fit χ2 test, while the χ2 test of indepen-
dence was computed using StatCalc software to compare 
the genotype and allele frequencies between study groups. 
Logistic regression analysis was performed to determine the 
association of the Pro12Ala variant with disease onset and 
severity by using EpiCalc software.
RESULTS
Ethnic background and average age were matched between 
the study groups consisting of 180 individuals with DR, 193 
individuals with DNR, and 200 controls (NGNR; p>0.05, 
data not shown). Out of the 180 subjects with DR, half (n=90) 
had NPDR, and the other half were diagnosed with PDR. 
The genotype frequency of the control (NGNR) group was 
consistent with Hardy–Weinberg equilibrium.
In the present study, the frequency of the 12Ala homozy-
gotes was highest in the DNR group (overall: n=8 [4%], male: 
n=6 [6.4%], female: n=2 [2%]) followed by controls (n=2 [1%]; 
both of whom were male), while no 12Ala homozygote was 
found in the DR group (Table 1). Thus, logistic regression 
analysis was performed assuming a dominant model for 
12Ala for genotype association, and allele frequencies were 
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compared. Analysis of the DR and control subjects showed 
no significant association (p>0.05), although genotype 
frequency distribution was significantly different (p<0.05) 
among women. Similarly, there was no genotype or allele 
association in a comparison between the DNR group and the 
controls. A significant protective effect (p<0.05) of 12Ala 
was observed in a DR versus DNR comparison after adjusting 
for age and gender in an overall analysis, which diminished 
in the gender-based data analysis (p>0.05; Table 1). To deter-
mine the association of the variant with T2DM irrespective 
of the presence or absence of microvascular complication, 
a comparison of subjects with T2DM (DR+DNR) was 
performed against the control group, which revealed a non-
significant association (Table 2).
In further analysis, the DR group was divided into 
two subsets, NPDR and PDR, and each was independently 
analyzed against the DNR group and the control group (Table 
3). The 12Ala allele was not associated with NPDR in both 
comparisons. The analysis of the PDR subgroup also showed 
no association with 12Ala compared with the control NGNR 
group, while a significant protective effect (p<0.05) of the 
variant was seen compared to the DNR group. A case-only 
comparison between the PDR and NPDR groups was also 
performed that showed a non-significant genotype difference 
between the two sub-groups (Table 3).
DISCUSSION
PPARγ, a nuclear receptor, has a major role in transcriptional 
regulation of genes involved in various physiologic processes 
of clinical significance such as adipogenesis, inflammation, 
and angiogenesis. The non-synonymous single nucleotide 
polymorphism (SNP) rs1801282 (c.34C>G, p.Pro12Ala) in 
exon 4 of the PPARγ2 isoform has been associated with the 
etiology of T2DM and its complications. However, the asso-
ciation with DR has been inconsistent; therefore, we studied 
this SNP in Pakistani subjects with T2DM. The frequency of 
the 12Ala allele in the current study was low (12%) in accor-
dance with the frequency in other populations, e.g., highest 
(about 12%) in Caucasians followed by 10% in Mexican 
Americans, 8% in Samoans, 3% in African Americans, 2% 
in Nauruans, and 1% in Chinese (the lowest) [24].
The 12Ala isoform of PPARγ had been found to have 
a protective role against diabetic nephropathy, another 
common T2DM complication [25]. In the present analysis, 
we also found a protective role of the 12Ala variant in the 
onset of PDR among individuals with T2DM. This finding is 
consistent with Malecki et al. [26] and contradicts others who 
Table 2. associaTion of pro12ala polymorphism of pparγ wiTh The risk of T2dm.
T2DM T2DM versus Controls
n=373 χ2 (p) OR(95%CI)
Pro/Pro 292(78.3%) 1.23 DM=0.96(0.62–1.48)
Pro/Ala 73(19.6%) (0.54)
Ala/Ala 8(2.1%)
Pro 657(88%) 0.01 1.02(0.69–1.51)
Ala 89(12%) (0.93)
Males n=181
Pro/Pro 137(75.7%) 2.48 DM=1.37(0.72–2.62)
Pro/Ala 38(21%) (0.29)
Ala/Ala 6(3.3%)
Pro 312(86%) 1.28 1.37(0.77–2.44)
Ala 50(14%) (0.26)
Females n=192
Pro/Pro 155(80.7%) 3.32 DM=0.68(0.37–1.25)
Pro/Ala 35(18.2%) (0.19)
Ala/Ala 2(1.04%)
Pro 345(90%) 1.08 0.76(0.43–1.33)
Ala 39(10%) (0.3)
Pro: C allele; Ala: G allele; χ2: Chi-square test of independence; OR(95%CI): Odds Ratio (95% Confidence Interval); DM: Dominant 
Model (Pro/Ala+Ala/Ala versus Pro/Pro)
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found no association of this variant with DR [13,21,27]. In a 
meta-analysis, the Pro12 isoform conferred a risk for T2DM 
by 1.25-fold compared to 12Ala [18]. However, in the present 
study, we did not find a higher prevalence of either isoform 
in the patients with T2DM compared to the control NGNR 
group. The 12Ala variant has also been shown to reduce the 
risk of atherosclerosis in subjects susceptible to diabetes [28] 
and against myocardial infarction in non-diabetic individuals 
[29]. Although the existing evidence points to a possible 
protective role of the 12Ala variant in the development of 
proliferative diabetic retinopathy, the underlying mechanism 
of this effect is still unknown. One possible explanation is the 
relation of this isoform with a reduction in insulin resistance 
[16], a known predisposing factor for diabetic complications 
including DR [5]. In a clinical study, Parvanova et al. [30] 
reported the level of insulin sensitivity was an independent 
risk factor for PDR and not NPDR, which also corroborate 
our results of a significant risk reduction, in 12Ala-carrying 
subjects with T2DM, confined to PDR only, and no associa-
tion with NPDR.
However, the protective role of PPARγ manifested by 
its reduced transactivation activity due to the 12Ala varia-
tion [14,31] contradicts the known role of PPARγ in disease 
pathology. For instance, Muranaka et al. [7] showed that upon 
ligand activation, PPARγ reduces leukostasis and leakage 
in retinal vasculature. In a streptozotocin-induced diabetic 
mouse model, the authors observed 2.1 times raised levels 
of retinal leukostasis and 1.9 times greater retinal leakage in 
PPARγ+/− mice compared to wild-type, thus demonstrating 
possible evidence of some intrinsic role being played by 
PPARγ in DR. The researchers also observed a 0.6-fold 
reduction each in retinal leukostasis and retinal leakage 
upon treatment of diabetic mice with PPARγ ligand rosigli-
tazone. To define the underlying mechanism, the researchers 
investigated the effect on inflammatory markers and found a 
reduction in raised intercellular adhesion molecule 1 levels in 
rosiglitazone-treated mice. This finding highlights the anti-
inflammatory actions of PPARγ, which could perhaps provide 
protection against DR. However, streptozotocin-induced 
diabetes is a T1DM model [32], while insulin resistance char-
acterizes T2DM. Thus, PPARγ might have different roles in 
Table 3. analysis of associaTion of pro12ala polymorphism of pparγ wiTh npdr and pdr.
NPDR NPDR versus Controls NPDR versus DNR
n=90 χ2 (p) OR(95%CI) χ2 (p) OR(95%CI)
Pro/Pro 71(79%) 0.92 DM=0.92(0.5–1.69) 3.93 DM=0.77(0.40–1.45)
Pro/Ala 19(21%) (0.63) (0.14)
Ala/Ala 0
Pro 161(89%) 0.18 0.89(0.48–1.61) 2.09 0.67(0.37–1.19)
Ala 19(11%) (0.68) (0.15)
PDR PDR versus Controls PDR versus DNR
n=90
Pro/Pro 78(86.7%) 3.73 DM=0.53(0.23–1.1) 7.26 DM=0.44(0.21–0.91)
Pro/Ala 12(13.3%) (0.15) (0.03)
Ala/Ala 0
Pro 168(93%) 3.51 0.54(0.26–1.08) 7.91 0.4(0.2–0.8)
Ala 12(7%) (0.06) (0.005)
PDR versus NPDR
Pro/Pro - 1.91 DM=0.57(0.24–1.4)
Pro/Ala - (0.17)
Ala/Ala -
Pro - 1.73 0.61(0.27–1.36)
Ala - (0.19)
Pro: C allele; Ala: G allele; χ2: Chi-square test of independence; OR(95%CI): Odds Ratio (95% Confidence Interval); DM: Dominant 
Model (Pro/Ala+Ala/Ala versus Pro/Pro); Statistically significant values (p≤0.05) are written in bold.
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T1DM and T2DM. In addition, since 12Ala is found in the 
ligand-independent domain, the effects are independent of the 
presence or absence of PPARγ ligands [31,33], e.g., rosigli-
tazone. Therefore, improvement in insulin sensitivity might 
be the defining factor, implicating the protective effect of the 
12Ala variant against disease proliferation in individuals with 
T2DM who have retinopathy.
Since PPARγ2 is exclusively expressed in the adipose 
tissue, any effects of this variant on insulin resistance are 
secondary, pointing to the involvement of some intermediate 
link such as reduction in the release of free fatty acids from 
adipose tissue by suppressing lipolysis upon insulin stimula-
tion. These reduced free fatty acid levels then result in more 
efficient glucose oxidation by muscle cells and decreased 
glucose production by liver cells in response to insulin 
[34-36], thus improving insulin sensitivity [9], which may 
subsequently ameliorate the pathophysiological basis of DR 
progression.
In addition, a link between the dietary habits and T2DM 
risk in relation to the Pro12Ala polymorphism was shown 
by Scacchi et al. [37], who found T2DM to be less preva-
lent among 12Ala carriers of populations who obtain more 
than 30% of their energy from dietary lipid intake, while 
those with less than 30% exhibited no clear pattern. The 
Pakistani population lies in the latter category where energy 
obtained from dietary lipids constitutes less than 30% of the 
total (FAO. Statistical Yearbook); therefore, in the Pakistani 
population, the possibility of such a link cannot be excluded 
in describing the relationship between dietary habits and the 
prevalence of T2DM and PDR among 12Ala carriers. In addi-
tion, in diabetics the protective effect of the 12Ala allele has 
been shown to be altered by the presence of another genetic 
variation, the T1431 synonymous SNP (rs3856806), in exon 
6 of the gene [38]. The T1431 is in strong linkage disequilib-
rium with 12Ala, where the protective effects of the 12Ala 
allele are absent in individuals with the 1431T allele [39]. 
Therefore, such findings suggest a variable role of 12Ala in 
diabetes and its related complications, which requires further 
genetic elucidation in the Pakistani population.
In conclusion, we report a protective effect of 12Ala 
against PDR among individuals with T2DM. These effects 
were non-significant when compared to the subjects with 
NGNR, suggesting the putative relation of the phenotypic 
effects of this polymorphism with hyperglycemic conditions.
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